The blood thinner Pradaxa has generated about $1.48 billion in worldwide sales over a span of less than two years. According to a story in Bloomberg, that’s largely because manufacturer Boehringer Ingelheim has been marketing it as a more convenient alternative to an existing medication.
Unlike the blood thinner warfarin, which has been around since the 1950s, Pradaxa does not require frequent blood testing and dietary restrictions.
But plaintiffs in numerous ...
continue reading...A new study is reporting good results for extended use of the blood thinner apixaban produced by Pfizer Inc. and Bristol-Myers Squibb Co.
A Reuters story says researchers found the drug, sold under brand name Eliquis, reduced the risk of recurrence of potentially deadly clots in the veins and lungs by 80 percent, with no increase in major bleeding.
Apixaban is among a new class of blood thinners meant to replace ...
continue reading...A Bloomberg report says German pharmaceutical company Boehringer Ingelheim GmbH is now facing more than 150 lawsuits over claims that the company sold the blood thinner Pradaxa despite being aware that it could cause potentially deadly bleeding.
Plaintiffs’ lawyers say the company will probably end up facing thousands more lawsuits in coming years. According to the story, the drug has been linked to ...
continue reading...In an analysis piece for Forbes, journalist Ed Silverman writes that the U.S. Food and Drug Administration may have used a flawed statistical model in its evaluation of the bleeding risks for the drug Pradaxa.
Pradaxa is a blood thinner, used to prevent blood clots and strokes in patients with atrial fibrillation. The Institute for Safe Medicine Practices has linked the drug to more than 500 deaths and ...
continue reading...Patients who go on low-dose daily aspirin appear to be at lower risk of developing potentially deadly blood clots, according to a story in U.S. News and World Report.
The story concerns a study in which researchers combined the results of a small study with those of a similar trial, so that the combined data was large enough to test for trends. The combined study indicated that daily aspirin could ...
continue reading...According to Reuters, the U.S. Food and Drug Administration has set March 17 as the deadline for deciding whether to approve blood thinner Eliquis for patients with atrial fibrillation.
The agency declined to approve the drug in June, requesting that manufacturers Bristol-Myers Squibb Co and Pfizer Inc. provide more information on a pivotal clinical trial of the medicine, which is designed to reduce the risk of stroke caused by blood ...
continue reading...
